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Abstract
Objectives: Pediatric severe sepsis is a major cause of morbidity and mortality worldwide, and 
hematopoietic cell transplant patients represent a high-risk population. We assessed the 
epidemiology of severe sepsis in hematopoietic cell transplant patients, describing patient 
outcomes compared with children with no history of hematopoietic cell transplant.
Design: Secondary analysis of the Sepsis PRevalence, OUtcomes, and Therapies point 
prevalence study, comparing demographics, sepsis etiology, illness severity, organ dysfunction, 
and sepsis-related treatments in patients with and without hematopoietic cell transplant. The 
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primary outcome was hospital mortality. Multivariable logistic regression models were used to 
determine adjusted differences in mortality.
Setting: International; 128 PICUs in 26 countries.
Patients: Pediatric patients with severe sepsis prospectively identified over a 1-year period.
Interventions: None.
Measurements and Main Results: In patients with severe sepsis, 37/567 (6.5%) had a history 
of hematopoietic cell transplant. Compared with patients without hematopoietic cell transplant, 
hematopoietic cell transplant patients had significantly higher hospital mortality (68% vs 23%; p < 
0.001). Hematopoietic cell transplant patients were more likely to have hospital acquired sepsis 
and had more preexisting renal and hepatic dysfunction than non–hematopoietic cell transplant 
patients with severe sepsis. History of hematopoietic cell transplant, renal replacement therapy, 
admission from inpatient floor, and number of organ dysfunctions at severe sepsis recognition 
were independently associated with hospital mortality in multivariable analysis; hematopoietic cell 
transplant conferred the highest odds of mortality (odds ratio, 4.00; 95% CI, 1.78–8.98). In 
secondary analysis of hematopoietic cell transplant patients compared with other 
immunocompromised patients with severe sepsis, history of hematopoietic cell transplant 
remained independently associated with hospital mortality (odds ratio, 3.03; 95% CI, 1.11–8.27).
Conclusions: In an international study of pediatric severe sepsis, history of hematopoietic cell 
transplant is associated with a four-fold increased odds of hospital mortality after adjustment for 
potential measured confounders. Hematopoietic cell transplant patients more often originated from 
within the hospital compared to children with severe sepsis without hematopoietic cell transplant, 
possibly providing an earlier opportunity for sepsis recognition and intervention in this high-risk 
population.
Keywords
epidemiology; hematopoietic cell transplantation; immunocompromised host; multiple organ 
dysfunction syndrome; severe sepsiss
Pediatric severe sepsis is a common indication for admission to the PICU, and it remains a 
significant cause of morbidity and mortality in children worldwide (1, 2). Recent data 
estimate that 8% of children receiving critical care around the world have severe sepsis at 
any given time (3), and mortality estimates for children with severe sepsis range between 
10% and 25% (3, 4). The prevalence of severe sepsis in children is increasing (5), and 
consensus guidelines emphasizing prompt recognition and treatment of severe sepsis (6) 
have led to improvements in sepsis-related morbidity and mortality (5, 7, 8).
Hematopoietic cell transplant (HCT) patients represent a particularly high-risk cohort of 
PICU patients; recipients have poor outcomes regardless of their indication for PICU 
admission (9–11). Data from retrospective cohorts have demonstrated increased morbidity 
and mortality in subsets of septic patients with malignancy (12), congenital 
immunodeficiency (13), and HCT (14). Unfortunately, retrospective identification of patients 
with severe sepsis is problematic (15), which may limit the reliability of retrospective 
reports. Several studies have prospectively enrolled children with severe sepsis (16–21), 
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although none have specifically evaluated patients for comorbidities associated with immune 
dysfunction, including history of HCT, and some specifically exclude those with immune 
compromise or history of HCT (4). Based on the available literature, it is difficult to draw 
broad generalizations about the epidemiology of severe sepsis in HCT patients, to determine 
if the treatments and supportive care used for HCT patients with severe sepsis are different 
than those used for immunocompetent children, and to assess clinically relevant outcomes in 
this population.
The Sepsis PRevalence, OUtcomes, and Therapies (SPROUT) point prevalence study was a 
large, multicenter, prospective study to assess the burden of pediatric severe sepsis 
worldwide. Results from that study demonstrated 25% hospital mortality among patients 
with severe sepsis and new moderate-to-severe disability at hospital discharge in 17% of 
survivors (3). In our analysis, we assessed the prevalence of HCT among children with 
severe sepsis in the SPROUT study and described outcomes in HCT patients versus patients 
without HCT, comparing demographics, sepsis etiology, illness severity, organ dysfunction, 
sepsis-related treatments, disability, and mortality. We hypothesized that prior HCT would 
be an independent risk factor for mortality and that HCT recipients would develop more 
end-organ dysfunction, receive more intensive therapies, and experience higher levels of new 
moderate-to-severe disability than SPROUT subjects without a history of HCT. We also 
hypothesized that HCT would remain an independent risk factor for mortality in a 
subanalysis of immunocompromised patients with sepsis.
MATERIALS AND METHODS
Study Design
The SPROUT study was a prospective, cross-sectional point prevalence study with 90-day 
follow-up for measurement of outcomes performed in 128 PICUs in 26 countries on 5 study 
days spaced throughout 2013 and 2014 (3). Sites were recruited by open invitation, and 
participation was voluntary. Ethical approval was obtained at all study sites, and waiver of 
informed consent was granted at all but three sites, at which written consent was required for 
data collection. The details of the SPROUT study methodology have been published 
previously (3).
Data Collection
On each study day, PICU patients less than 18 years old were screened for severe sepsis 
according to consensus criteria (22) using data from the 24 hours preceding the study day, 
yielding a study cohort of patients with active severe sepsis. Infants less than 42 weeks 
corrected gestational age, and patients who received cardiopulmonary bypass in the 
preceding 5 days were excluded. For patients meeting inclusion criteria, demographics were 
collected from the time of PICU admission. Vital signs, laboratory results, and therapeutic 
interventions were captured within a 48-hour period around the study day (from 9:00 AM the 
day prior to 9:00 AM the day after). Detailed HCT-related data, including date of transplant, 
indication for transplant, type of transplant, source of cells, and conditioning regimen, were 
not collected. The date of severe sepsis recognition was determined by retrospective medical 
record review at the time of study enrollment. To determine severity of illness, the Pediatric 
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Index of Mortality (PIM)-2 score (23) and PIM-3 score (24) were calculated from PICU 
admission. The Pediatric Logistic Organ Dysfunction score (25) was calculated on the study 
day. The presence of multiple organ dysfunction syndrome was assessed using published 
definitions (26) on the day of severe sepsis recognition, and the development of organ 
dysfunction was assessed for the next 7 days. The Pediatric Overall Performance Category 
(POPC) ordinal scale (27) was used to calculate baseline disability and disability at hospital 
discharge for all hospital survivors. Patients were followed until hospital discharge (censored 
at 90 d if still hospitalized) to determine clinical outcomes. Details of the Goldstein criteria 
for severe sepsis and the Proulx criteria for multiple organ dysfunction syndrome are shown 
in eTable 1 (Supplemental Digital Content 1, http://links.lww.com/PCC/A530) and eTable 2 
(Supplemental Digital Content 1, http://links.lww.com/PCC/A530), respectively.
Exposure
Patients with a documented history of HCT were assigned to the HCT cohort. History of 
HCT was identified through medical record review at the time of study enrollment and 
included patients who received autologous or allogeneic HCT at any time prior to study 
enrollment, regardless of indication for transplant and source of cells. All other patients with 
severe sepsis were assigned to the reference cohort. A secondary analysis was performed in 
the subset of immunocompromised SPROUT patients, comparing those with a history of 
HCT to immunocompromised patients with no history of HCT. Immunocompromised 
diagnoses included malignancies, solid organ transplants, and congenital 
immunodeficiencies.
Patient Outcomes
The primary outcome was all-cause hospital mortality at hospital discharge, censored at 90 
days. Secondary outcomes included PICU mortality, PICU length of stay (LOS), hospital 
LOS, PICU-free days, vasoactive-free and ventilator-free days out of 28 from the day of 
severe sepsis recognition, and new mild or moderate disability measured by change in 
POPC.
Statistical Analysis
Data are presented as medians with interquartile ranges (IQRs) for continuous variables and 
frequencies with proportions for categorical variables. Comparisons between groups were 
performed using the Wilcoxon rank-sum test for continuous variables and Fisher exact test 
or chi-square test as appropriate categorical variables. Multivariable logistic regression was 
performed to test the association of HCT with the binary outcome of hospital mortality. 
Covariates were identified a priori based on biologic plausibility and observed differences 
between patients with and without HCT. We defined a confounder as a covariate that 
changed the odds ratio (OR) of the association between HCT and mortality by greater than 
or equal to 10%. The following covariates were tested for confounding: age, geographic 
region, number of organ dysfunctions at the time of severe sepsis recognition, viral sepsis 
etiology, presence of bacteremia, treatment with renal replacement therapy (RRT), and 
admission from an inpatient floor. Treatments that were expected to differ between groups 
on the basis of a history of HCT (e.g., blood product and IV immune globulin [IVIG] 
administration) were not included in the multivariable model. Although age did not meet our 
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a priori criteria for confounding, it was included in all final models. A second multivariable 
model was constructed for the subset of immunocompromised patients using the same 
methodology. Data were analyzed using Stata (v12.1; StataCorp LLC, College Station, TX).
RESULTS
Prevalence of HCT and Associated Conditions
In the SPROUT study, 6,925 patients were screened and 569 were identified who met 
consensus criteria for active severe sepsis (3). Two patients declined consent for data 
collection, and detailed data were collected on 567 patients (Table 1). Of these, 37 (6.5%) 
had a history of HCT. HCT patients were older, were more frequently admitted from the 
inpatient ward, and were more likely to have renal and hematologic dysfunctions (26) at the 
onset of severe sepsis (Table 2). HCT patients had significantly higher median PIM-3 score 
(10.6 vs 3.9; p < 0.001); however, PIM-2 score, which does not adjust for HCT, was not 
significantly different between groups. Although there was no significant difference in the 
primary site of infection between cohorts, HCT patients were more likely than non-HCT 
patients to have documented bacteremia (41% vs 23%; p = 0.018) and viral infections (41% 
vs 20%, p = 0.003), as shown in Table 3.
HCT Was Associated With Hospital Mortality and Prolonged LOS
The primary outcome, hospital mortality, occurred significantly more frequently in HCT 
patients in our cohort (68% vs 23%; p < 0.001) (Table 4). PICU and hospital mortality were 
high among HCT patients despite similar PICU LOS and similar ventilator-free days and 
vasoactive infusion-free days in the 28 days following severe sepsis recognition. Among 
non-survivors, median hospital LOS was significantly higher in the HCT group, though 
PICU LOS was similar between groups. Stratification by mortality revealed a bimodal 
distribution of PICU LOS in HCT patients (eTable 3, Supplemental Digital Content 1, http://
links.lww.com/PCC/A530), with a much higher median LOS in children who died in the 
PICU (23 d [IQR, 12–56]) compared with those who were discharged alive (6.5 d [IQR, 3.5–
23]). Median PICU-free days for HCT patients were significantly fewer than the reference 
cohort, and Figure 1 shows the cumulative incidence of being discharged from the PICU 
alive among HCT patients versus patients without HCT (Fig. 1A) and among HCT patients 
versus immunocompromised patients without HCT versus immunocompetent patients (Fig. 
1B). No difference in moderate-to-severe disability among survivors was noted between the 
cohorts (Table 4). Multivariable logistic regression identified history of HCT, number of 
organ dysfunctions at recognition of severe sepsis, RRT, and admission from an inpatient 
floor as independent variables associated with hospital mortality in patients with severe 
sepsis (Table 5). After adjustment for confounders, the odds of hospital mortality were four-
fold higher in HCT patients compared to patients without HCT (adjusted OR, 4.00; 95% CI, 
1.78–8.98; p = 0.001).
HCT Patients Developed Sepsis While Hospitalized
In our cohort, HCT patients were more than twice as likely to be admitted from an inpatient 
ward compared to patients without HCT (73% vs 25%) (Table 1). Among HCT patients with 
severe sepsis, median PIM-3 score was higher in those patients admitted from an inpatient 
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ward than those admitted from another source (4.6 [IQR, 2.1–10.6] vs 3.8 [IQR, 1.5–7.7]; p 
= 0.001). In the multivariable analysis, admission from an inpatient ward was independently 
associated with mortality among patients with severe sepsis (Table 5).
New Organ Dysfunction Is More Common in HCT Patients
Rates of organ dysfunction were assessed at multiple times and by multiple definitions, as 
shown in Table 2. When compared with the reference cohort, there was more preexisting 
renal dysfunction and hepatic dysfunction defined by Proulx criteria (26) in HCT patients, 
while rates of cardiovascular and respiratory dysfunctions were similar across groups. The 
total number of organ dysfunctions defined by Proulx criteria at the time of severe sepsis 
recognition was higher among HCT patients, accounted for by preexisting hematologic, 
hepatic, or renal dysfunction. In all categories of organ dysfunction, there was no difference 
in the timing of new organ dysfunction onset relative to severe sepsis recognition in those 
who had organ dysfunction (not shown). HCT patients had significantly more renal 
dysfunction present at the time of severe sepsis recognition than the reference cohort (54% 
vs 18%; p < 0.001), both new renal dysfunction (30% vs 11%; p = 0.001) and preexisting 
renal dysfunction (24% vs 7%; p = 0.002).
HCT Patients Were Exposed to High-Risk Therapies During Treatment for Sepsis
Despite similar PICU LOS, ventilator-free days, and vasoactive infusion-free days in the 28 
days following severe sepsis recognition, HCT patients were more frequently exposed to 
RRT, corticosteroids, insulin, blood products, colony-stimulating factors, and IVIG. As 
noted above, renal dysfunction was more common among HCT patients, and 38% of HCT 
patients were treated with RRT. HCT patients also received less enteral nutrition (EN) (38% 
vs 60%; p = 0.009) and more parenteral nutrition (PN) (78% vs 36%; p < 0.001) than non-
HCT patients. There were not differences, however, between the use of mechanical 
ventilation, vasoactive infusion, or central, arterial, and bladder catheters between patients 
with and without HCT (eTable 4, Supplemental Digital Content 1, http://
links.lww.com/PCC/A530).
Subanalysis of Immunocompromised Patients With Severe Sepsis
Secondary analysis restricted to the subpopulation of immunocompromised SPROUT 
patients shows similar results to the overall cohort. When compared with 
immunocompromised patients without HCT (n = 91), HCT patients were more likely to be 
admitted from an inpatient ward and had more organ dysfunction at the time of severe sepsis 
recognition but did not have higher PIM-2 scores (eTable 5, Supplemental Digital Content 1, 
http://links.lww.com/PCC/A530). HCT patients did not have bacteremia more frequently but 
had a higher proportion of viral infections when compared with other immunocompromised 
patients (eTable 6, Supplemental Digital Content 1, http://links.lww.com/PCC/A530). 
Hospital mortality among HCT patients was much higher than among other 
immunocompromised patients (68% vs 31%; p < 0.001) despite similar ventilator-free days 
and vasoactive infusion-free days (eTable 7, Supplemental Digital Content 1, http://
links.lww.com/PCC/A530).
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A second multivariable logistic regression model evaluated the independent association of 
HCT with hospital mortality within the subpopulation of SPROUT patients with 
immunocompromising conditions. In this analysis, history of HCT remained a significant 
independent risk factor for hospital mortality (OR, 3.03; 95% CI, 1.11–8.27), along with 
RRT, insulin therapy, and admission from an inpatient floor (Table 6). Differences were also 
seen in the cumulative incidence of being discharged alive between HCT patients and other 
immunocompromised patients without HCT (eFig. 1, Supplemental Digital Content 2, http://
links.lww.com/PCC/A531; legend, Supplemental Digital Content 1, http://
links.lww.com/PCC/A530).
DISCUSSION
A history of HCT was present in approximately 7% of patients with severe sepsis and was 
independently associated with a four-fold increased odds of hospital mortality in this cohort. 
This association remained significant in secondary analysis restricted to only 
immunocompromised patients. Notably, in this study of severe sepsis, the reference cohort is 
a medically complex patient population, with 22% being previously healthy patients. Thus, 
the elevated mortality risk associated with a history of HCT is significant in comparison to 
other patients with complex chronic conditions frequently cared for in PICUs around the 
world. Our secondary multivariable logistic regression analysis suggests that the mortality 
risk associated with HCT is not merely explained by immune dysfunction, as there is a 
significantly increased risk of mortality associated with HCT even compared with other 
immunocompromised patients with severe sepsis.
Poor outcomes among HCT patients with sepsis are consistent with previously published 
literature (14). Although this finding has been consistently reported, its precise cause 
remains poorly understood. HCT patients are exposed to multiple antibiotics placing them at 
risk for multidrug resistant organisms (28). Our study did not collect antibiotic sensitivity 
data and thus cannot assess questions of antibiotic resistance, but it is plausible that the 
bacterial organisms causing sepsis in HCT patients were resistant to the initial parenteral 
antibiotic. However, many of the patients in this study had sepsis due to viral infections, and 
their clinical outcomes were not different than patients with bacterial infections.
Although differences in type and site of infection were not independently associated with 
mortality in this study, the higher rates of viral infection and bacteremia in the HCT cohort 
likely reflect differences in risk factors for infection specific to patients with prior HCT. T-
cell depletion following HCT is well documented (29) and could explain the higher 
prevalence of viral illnesses in HCT patients in this study. Of note, HCT patients had higher 
rates of leukopenia than non-HCT patients in our cohort. The higher rates of bacteremia 
observed in our HCT patients may be related to the higher rates of indwelling central venous 
catheters, which have also been described as clear risk factors for bacteremia among 
immunocompromised patients (30).
Another possible factor leading to inferior outcomes among HCT patients with severe sepsis 
is that sepsis can serve as a trigger for inflammation-associated complications of HCT, 
including graft versus host disease (GVHD) and thrombotic microangiopathy (TMA). 
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GVHD is a common complication of HCT, with up to 50% of allogeneic HCT patients 
developing grade II–IV GVHD. Steroid-refractory GVHD has a very poor survival rate of 
less than 30% (31), and one of the described triggers for GVHD is infection. The intestinal 
microbiome seems to also play an important role in GVHD (32), and HCT patients with 
sepsis may have alterations in the microbiome secondary to antibiotics and lack of enteral 
feeds, among other factors. Broad-spectrum antibiotics have been shown to increase the 
mortality in patients with GVHD (31). Due to emerging antibiotic resistance, the increased 
risk of mortality associated with exposure to broad-spectrum antibiotics, and the high rates 
of mortality associated with sepsis in HCT patients, proper antimicrobial stewardship is both 
difficult and imperative for HCT patients.
TMA is an increasingly recognized complication of HCT. TMA is characterized by 
microangiopathic hemolytic anemia, thrombocytopenia, and thrombi in the microcirculation. 
Severe TMA carries a mortality rate up to 80%, may cause multiple organ failure, and is 
associated with complement activation (33). The etiology is thought to be due to endothelial 
damage caused during transplant conditioning, immunosuppressive agents, GVHD, and/or 
infection (34). It is possible that the increased mortality seen in HCT patients with sepsis 
could in part be due to the infection triggering TMA or GVHD, both significant 
complications with very high mortality rates.
This study also identified admission from an inpatient ward as an independent risk factor for 
mortality in patients with severe sepsis. Patients with HCT were more likely to be admitted 
from inpatient wards than patients without HCT, and HCT patients admitted from inpatient 
wards had higher PIM-3 scores than HCT patients admitted from other locations. In 
multivariable analysis, source of admission was independently associated with mortality in 
patients with severe sepsis. These findings support results from a recent prospective study 
from South America which demonstrated an association between admission from an 
inpatient ward and hospital mortality in pediatric severe sepsis (18). These observations 
suggest that future research priorities should focus on the impact of earlier recognition and 
intervention of severe sepsis in the inpatient setting. Earlier transfer to the PICU for 
hemodynamic monitoring and comprehensive sepsis care by a team of pediatric intensivists 
and transplant physicians may be beneficial in these high-risk patients.
The diagnosis of sepsis may also be more challenging in HCT patients than in other 
populations, and delayed recognition and initiation of sepsis therapies may also contribute to 
the high mortality rates seen in this population. In our cohort, HCT patients had more 
preexisting organ dysfunction, likely due to their primary disease, prior chemotherapy, 
transplant conditioning, and transplant-related complications. In these high-risk, medically 
complex children, delayed diagnosis due to multiple other active medical problems must be 
considered in addition to their comorbid immune dysfunction when considering potential 
explanations for sepsis-related mortality among HCT patients.
Data from this study also demonstrate that children with sepsis and HCT experience a long 
LOS in PICU, particularly among nonsurvivors. This pattern is consistent with a recently 
described epidemiologic trend within the PICU population; although crude mortality in 
PICUs is falling, the PICU LOS of nonsurvivors is steadily increasing (35). The combination 
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of high PICU mortality rate (> 60%) and long PICU LOS in patients with HCT raises 
questions about the experience of patients and family. Priorities for further research should 
focus on identifying interventions to reduce mortality and identifying cases in which 
treatment may be futile. Traditional PICU admission illness severity scores, designed for 
population not individual mortality risk assessment, are likely not useful in this regard. 
Although PIM-3 score was more accurate than PIM-2 score in predicting the increased 
mortality risk associated with HCT patients with severe sepsis, both scores significantly 
underestimated the risk of hospital mortality in patients with severe sepsis, particularly in 
those with prior HCT.
Baseline organ dysfunction was more frequent in HCT patients, and new renal dysfunction 
was also more common in this patient population. Renal dysfunction has been previously 
described as a risk factor for death in patients with severe sepsis (36). In our cohort, nearly 
all HCT patients with renal dysfunction received RRT. Based on these findings, septic 
patients with prior HCT and new renal dysfunction are very likely to require RRT. Further 
investigation into early initiation of RRT may be warranted in these patients.
In this study, HCT patients received significantly more PN and less EN than the comparison 
group. Prior studies have demonstrated a beneficial association with early EN and survival in 
critically ill children (37) and potential harm with early PN (38). There are likely a multitude 
of reasons that the HCT patients received less EN than the comparison group, though this 
study did not capture those reasons. The HCT population may not have received EN due to 
GVHD of the gastrointestinal tract, a common post-HCT complication; frequently, children 
post HCT have poor oral intake and are placed on PN to supplement their caloric intake; and 
enteral tract dysfunction requiring PN is common post HCT. Although there were similar 
amounts of gastrointestinal dysfunction by Proulx criteria between groups, enteral feeding 
intolerance may not meet the strict gastrointestinal dysfunction criteria used in this study. As 
a majority of HCT patients originated from another hospital ward, they may have presented 
in severe sepsis while already receiving PN. This study is limited in that is does not track the 
timing of EN versus PN, and some patients likely received both simultaneously. The safety 
of enteral feeding in HCT patients has been established (39), though enteral feeding 
practices vary by center. Future studies of nutrition in children with severe sepsis could 
assess the safety of targeted EN and PN support in HCT patients.
Although the SPROUT study has several methodologic strengths, including international 
scope, prospective clinical diagnosis of severe sepsis based on consensus criteria, and a 90-
day follow-up period allowing for analysis of meaningful, patient-centered outcomes, there 
are some important limitations of this study. The SPROUT study did not collect information 
regarding indication for HCT, type of transplant, source of cells, conditioning regimen, and 
transplant complications. Inclusion of these variables could allow for further risk-
stratification of HCT patients, as recent reports have highlighted the heterogeneity of risk for 
transplant-related mortality based on patient comorbidities and HCT characteristics (40). 
Because of the international scope of our study, around half of the participating sites do not 
provide care for HCT patients, and thus HCT patients represent a relatively small proportion 
of patients with severe sepsis in our cohort. In our subanalysis of immunocompromised 
patients, immunocompromising diagnoses were identified by chart review and did not 
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include robust measures of immune dysfunction. Finally, limited sample size did not allow 
for analysis of variations in supportive care among geographic regions, which could impact 
outcomes for children with severe sepsis after HCT.
CONCLUSIONS
In this international study of pediatric severe sepsis, a history of HCT, after adjustment for 
potentially measured cofounders, is independently associated with a four-fold increased 
odds of hospital mortality. HCT patients also had more organ dysfunction and were treated 
with more RRT. Due to the small number of survivors in the HCT group, comparison of new 
disability in severe sepsis survivors was limited. Notably, HCT recipients with severe sepsis 
were more likely to be hospitalized and have preexisting organ dysfunction at recognition of 
sepsis, which may provide a unique opportunity for earlier monitoring, recognition, and 
intervention. Future investigation of severe sepsis in HCT should include HCT-specific 
monitoring approaches and interventions. Physicians caring for HCT patients must continue 
to engage in collaborative investigations and therapeutic strategies to improve recognition 
and earlier intervention for this high-risk population.
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Cumulative discharges alive by cohort, from PICU admission to discharge. Lines represent 
the cumulative rate of survival to discharge. The x-axis shows PICU length of stay. A, 
Compares hematopoietic cell transplant (HCT) patients to patients without HCT. B, Divides 
the cohort into HCT patients, immunocompromised patients without HCT, and 
nonimmunocompromised patients. Six patients who survived PICU admission but later died 
in the hospital could not be assessed based on the method of data collection and are 
excluded from this figure. IC = immunocompromised.
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